8-K: Summit Therapeutics' Partner Akeso Receives Chinese Approval for Ivonescimab in Lung Cancer Treatment

The National Medical Products Administration (NMPA) in China has approved ivonescimab in combination with chemotherapy for specific lung cancer patients, marking the first regulatory approval for the drug.

Summary

• The National Medical Products Administration (NMPA) in China has approved ivonescimab in combination with chemotherapy for patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI).
• This approval is based on the HARMONi-A (AK112-301) Phase III clinical trial conducted in China by Akeso, Inc., Summit Therapeutics' partner.
• The trial compared ivonescimab plus chemotherapy to placebo plus chemotherapy.
• Patients receiving ivonescimab plus chemotherapy showed a median progression-free survival (PFS) of 7.06 months, compared to 4.80 months for those receiving chemotherapy alone, with a hazard ratio of 0.46.
• Grade 3 treatment emergent adverse events (TEAEs) were more frequent in the ivonescimab group (61.5%) compared to the chemotherapy-only group (49.1%).
• The most common grade 3 TEAEs were related to chemotherapy.
• Additional data, including response rates and overall survival, will be presented at the 2024 ASCO Annual Meeting on May 31, 2024.
• Ivonescimab is not yet approved in Summit's licensed territories, including the United States, Canada, Europe, and Japan.
• The Chinese approval does not alter Summit's ongoing clinical development plans for ivonescimab in other regions.

Sentiment

Score: 7

Explanation: The document is positive due to the first regulatory approval of ivonescimab and the strong PFS results, but the higher rate of adverse events and lack of approval in other key markets temper the overall sentiment.

Positives

• Ivonescimab has received its first regulatory approval in China, demonstrating its potential efficacy.
• The HARMONi-A trial showed a statistically significant improvement in median progression-free survival (PFS) with ivonescimab plus chemotherapy compared to chemotherapy alone.
• The hazard ratio of 0.46 indicates a substantial reduction in the risk of disease progression with ivonescimab.
• The approval validates the clinical development strategy and potential of ivonescimab.

Negatives

• Grade 3 treatment emergent adverse events (TEAEs) were more frequent in the ivonescimab group (61.5%) compared to the chemotherapy-only group (49.1%).
• Ivonescimab is not yet approved in Summit's licensed territories, including the United States, Canada, Europe, and Japan.

Risks

• The higher incidence of Grade 3 treatment emergent adverse events (TEAEs) in the ivonescimab group may raise concerns about its safety profile.
• Regulatory approval in other key markets, such as the United States, is not guaranteed and will require further clinical trials and submissions.
• The success of ivonescimab in other regions will depend on the results of ongoing trials and regulatory reviews.

Future Outlook

Summit Therapeutics continues to enroll patients in its two multi-regional Phase III clinical trials (HARMONi and HARMONi-3) for ivonescimab in other regions. The Chinese approval does not change the timing or requirements of the trial process, or likelihood of approval, for ivonescimab in the United States, or Summits other license territories.

Industry Context

The approval of ivonescimab in China highlights the growing importance of targeted therapies in treating advanced lung cancer. This approval could potentially influence the development and regulatory pathways for similar treatments in other regions. The competitive landscape in lung cancer treatment is intense, with many companies developing novel therapies.

Comparison to Industry Standards

• The median PFS of 7.06 months for ivonescimab plus chemotherapy is a positive result when compared to the 4.80 months for chemotherapy alone in the HARMONi-A trial.
• Other EGFR-TKI treatments have shown varying PFS results, but the hazard ratio of 0.46 suggests a significant improvement with ivonescimab in this specific patient population.
• The 61.5% rate of Grade 3 TEAEs in the ivonescimab arm is higher than the 49.1% in the chemotherapy arm, which is a point of concern that will need to be further evaluated in comparison to other similar treatments.
• Companies like AstraZeneca with Tagrisso and Roche with Avastin are key competitors in the NSCLC space, and ivonescimab will need to demonstrate a strong safety and efficacy profile to compete effectively.

Stakeholder Impact

• Shareholders may view the Chinese approval positively, potentially leading to increased investor confidence.
• Patients in China with the specified type of lung cancer will have a new treatment option available.
• Employees of Summit Therapeutics may be encouraged by the progress of ivonescimab.
• Akeso, as the partner, will benefit from the commercialization of ivonescimab in China.

Next Steps

• Summit Therapeutics will continue to enroll patients in its ongoing Phase III clinical trials (HARMONi and HARMONi-3).
• Full data from the HARMONi-A trial will be presented at the ASCO Annual Meeting on May 31, 2024.
• Summit will continue to pursue regulatory approvals for ivonescimab in other regions.

Key Dates

Keywords

ivonescimab, lung cancer, NSCLC, NMPA, chemotherapy, EGFR, Akeso, HARMONi-A, PFS, clinical trial, regulatory approval